Axonics, Inc. (NASDAQ:AXNX) Receives Average Rating of “Hold” from Brokerages

Shares of Axonics, Inc. (NASDAQ:AXNX) have been given a consensus recommendation of “Hold” by the eight ratings firms that are presently covering the firm, Marketbeat reports. Eight analysts have rated the stock with a hold recommendation. The average twelve-month price objective among brokerages that have covered the stock in the last year is $71.00.

Separately, Needham & Company LLC reissued a “hold” rating on shares of Axonics in a report on Friday, November 8th.

Axonics Stock Performance

AXNX opened at $70.98 on Friday. The company’s 50-day simple moving average is $69.83 and its two-hundred day simple moving average is $68.54. The stock has a market capitalization of $3.63 billion, a P/E ratio of -591.50 and a beta of 0.82. Axonics has a 52-week low of $55.09 and a 52-week high of $71.05.

Insider Buying and Selling

In other Axonics news, CFO Kari Leigh Keese sold 2,961 shares of the firm’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $69.41, for a total transaction of $205,523.01. Following the completion of the transaction, the chief financial officer now owns 40,362 shares in the company, valued at $2,801,526.42. This trade represents a 6.83 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.85% of the stock is owned by company insiders.

Institutional Trading of Axonics

A number of large investors have recently made changes to their positions in the business. Headlands Technologies LLC raised its holdings in Axonics by 31.1% during the 1st quarter. Headlands Technologies LLC now owns 1,117 shares of the company’s stock valued at $77,000 after buying an additional 265 shares during the period. Xponance Inc. increased its position in Axonics by 7.5% during the second quarter. Xponance Inc. now owns 3,231 shares of the company’s stock valued at $217,000 after acquiring an additional 225 shares during the last quarter. Janney Montgomery Scott LLC purchased a new stake in shares of Axonics in the first quarter valued at $218,000. Entropy Technologies LP bought a new stake in shares of Axonics in the 3rd quarter worth about $395,000. Finally, Mercer Global Advisors Inc. ADV boosted its stake in shares of Axonics by 12.7% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 6,981 shares of the company’s stock worth $469,000 after purchasing an additional 785 shares during the period. 99.48% of the stock is currently owned by institutional investors.

Axonics Company Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.